Methods of using GIP / GLP1 co-agonists for treatment
By employing escalation and maintenance dosing regimens for tirzepatide, the problem of frequent gastrointestinal adverse events in GIP/GLP1 co-agonist therapy was addressed, resulting in effective glycemic control and weight management, and alleviating related chronic conditions.
Patent Information
- Application Number
- CN202511225442.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-03
- Filing Date
- 2019-07-22
- Publication Date
- 2025-11-25
AI Technical Summary
Existing GIP/GLP1 co-agonists for the treatment of type 2 diabetes are frequently associated with gastrointestinal adverse events, leading to dose limitations, which affect treatment efficacy and patient compliance. New dosage and dosing regimens are needed to achieve effective glycemic control and weight loss while maintaining safety.
The new tirzepatide dosing regimen includes an escalating dose and a maintenance dose administered approximately once weekly. The escalating dose is selected from approximately 2.5 mg, 7.5 mg, and 12.5 mg, and the maintenance dose is selected from approximately 5.0 mg, 10.0 mg, and 15.0 mg. By gradually increasing the dose, adverse events are reduced, and effective glycemic control and weight management are achieved.
It has achieved the goal of effectively reducing HbA1c levels and weight, slowing the progression of diabetes, and alleviating conditions such as chronic kidney disease, atherosclerosis, NAFLD, and NASH while maintaining safety.